Browse by author
Lookup NU author(s): Professor David BrooksORCiD
This is the authors' accepted manuscript of an article that has been published in its final definitive form by Springer US, 2018.
For re-use rights please refer to the publisher's terms and conditions.
Purpose: Recent evidence suggests that the tau radiotracer [18F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson’s disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding. Procedures: We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson’s disease patients who received MAO-B inhibitors with those who did not. Results: Sixteen of 27 Parkinson’s disease patients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels. Conclusion: Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.
Author(s): Hansen AK, Brooks DJ, Borghammer P
Publication type: Article
Publication status: Published
Journal: Molecular Imaging and Biology
Year: 2018
Volume: 20
Issue: 3
Pages: 356-360
Print publication date: 01/06/2018
Online publication date: 10/11/2017
Acceptance date: 01/09/2017
Date deposited: 15/01/2018
ISSN (print): 1536-1632
ISSN (electronic): 1860-2002
Publisher: Springer US
URL: https://doi.org/10.1007/s11307-017-1143-1
DOI: 10.1007/s11307-017-1143-1
Altmetrics provided by Altmetric
